Veranova, a global developer and manufacturer of complex APIs for the pharmaceutical and biotech sectors, has begun expanding its antibody-drug conjugate (ADC) and high potency compound development and manufacturing capabilities at its Devens, Massachusetts facility.
The investment — which is estimated at USD $30m — will build upon the site’s existing capabilities and expand the company’s global capacity to produce ADCs and other potent small molecules.
What’s new?
Veranova’s expansion will incorporate a novel high potency process development laboratory, as well as two new cGMP suites designed to handle potent compounds.
These facilities, which will be equipped to manage ADC linker-payloads and other complex molecules, will feature allocated air handling systems, airlocks for convenient cleaning, isolator technology and a range of processing capabilities, including:
- Synthesis reactors
- Chromatography
- Thin film evaporators
- Lyophilisation
CEO of Veranova, Mike Riley, commented: “At Veranova, we recognise the growing demand for development and manufacturing of ADCs and other highly potent compounds. Via this investment, we can provide capacity and capabilities to the market to ensure next generations therapies are reaching patients faster.”
Strategically located near the Boston pharmaceutical and biotech hub, Veranova’s Devens site is an FDA approved facility that boasts over 10 years of experience in the development, scale-up and clinical and commercial production of ADC linker-payloads and other highly potent APIs.
